Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Granulocyte-colony stimulating factor (G-CSF) is standard post-autologous progenitor cell transplantation to speed neutrophil recovery.
• Current practice often initiates G-CSF on the day of progenitor cell infusion (day 0).

Purpose of the Study:

• To evaluate the impact of initiating G-CSF on day 0, day +3, or day +5 after autologous peripheral blood progenitor cell (PBPC) transplantation on engraftment timelines.
• To assess potential cost savings associated with delayed G-CSF initiation.

Main Methods:

• Prospective, randomized trial involving 70 patients with breast cancer, non-Hodgkin's lymphoma, Hodgkin's disease, or multiple myeloma.
• Patients received chemotherapy-only preparative regimens and PBPC for hematopoietic reconstitution.
• G-CSF initiation was randomized to day 0, day +3, or day +5 post-transplant.

Main Results:

• Neutrophil engraftment occurred at a median of 10 days (day 0 group), 11 days (day +3 group), and 11 days (day +5 group).
• Platelet transfusion independence was achieved at a median of 14 days (day 0), 11 days (day +3), and 14 days (day +5).
• No significant differences in engraftment times were observed between the three G-CSF initiation schedules.

Conclusions:

• Delaying G-CSF initiation up to day +5 after autologous PBPC transplantation does not adversely affect neutrophil or platelet engraftment.
• Delayed G-CSF administration can lead to significant cost savings without compromising patient outcomes.